What is Catalyst Pharmaceutical's net change in cash?

Catalyst Pharmaceutical (CPRX) reported net change in cash of $46.69M in Q1 2026.

How has Catalyst Pharmaceutical's net change in cash changed year-over-year?

Catalyst Pharmaceutical's net change in cash decreased by 26.0% year-over-year, from $63.1M to $46.69M.

What is the long-term trend for Catalyst Pharmaceutical's net change in cash?

Over 3 years (2021 to 2025), Catalyst Pharmaceutical's net change in cash has grown at a 66.9% compound annual growth rate (CAGR), from $41.21M to $191.62M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Catalyst Pharmaceutical CPRX Net Change in Cash

Net Change in Cash at other companies

PTC TherapeuticsPTCT

-$147.9M-121%

Edgewise Therapeutics, Inc.EWTX

-$27.94M-438%

Acadia PharmaceuticalsACAD

$104.52M+203%

Dyne Therapeutics, Inc.DYN

-$140.25M-481%

Scholar RockSRRK

$106.35M+366%

Amneal Pharmaceuticals, Inc.AMRX

-$108.53M-117%

Other financials

Income statement

See full

Revenue$149.4M+5.6%

Gross profit$134.9M+9.2%

Operating income$73.2M+15.6%

Net income$63.7M+12.3%

EPS (diluted)$0.50+11.1%

Balance sheet

See full

Cash & equivalents$755.9M+30.2%

Total debt$2.7M-13.3%

Total equity$1.0B+27.5%

Total assets$1.1B+26.3%

Cash flow

See full

Operating cash flow$59.6M-0.8%

CapEx$27.0K—

Free cash flow$59.6M-0.8%

Valuation

See full

Market cap$3.84B+2.7%

Enterprise value$3.09B-4.1%

P/E17.4×-1.6×

P/S6.4×-0.6×

Profitability

See full

Gross margin86%-0.2pp

Operating margin44.8%+1.6pp

Net margin37.1%+0.2pp

FCF margin34.9%-15.2pp

Returns & leverage

See full

Return on equity24.5%-4.6pp

Debt / equity0×0.0×

Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Catalyst Pharmaceutical's net change in cash?: Catalyst Pharmaceutical (CPRX) reported net change in cash of $46.69M in Q1 2026.
How has Catalyst Pharmaceutical's net change in cash changed year-over-year?: Catalyst Pharmaceutical's net change in cash decreased by 26.0% year-over-year, from $63.1M to $46.69M.
What is the long-term trend for Catalyst Pharmaceutical's net change in cash?: Over 3 years (2021 to 2025), Catalyst Pharmaceutical's net change in cash has grown at a 66.9% compound annual growth rate (CAGR), from $41.21M to $191.62M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.